
PMID- 23741377
OWN - NLM
STAT- MEDLINE
DCOM- 20140218
LR  - 20211030
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Adult bone marrow neural crest stem cells and mesenchymal stem cells are not able 
      to replace lost neurons in acute MPTP-lesioned mice.
PG  - e64723
LID - 10.1371/journal.pone.0064723 [doi]
LID - e64723
AB  - Adult bone marrow stroma contains multipotent stem cells (BMSC) that are a mixed 
      population of mesenchymal and neural-crest derived stem cells. Both cells are 
      endowed with in vitro multi-lineage differentiation abilities, then constituting 
      an attractive and easy-available source of material for cell therapy in 
      neurological disorders. Whereas the in vivo integration and differentiation of 
      BMSC in neurons into the central nervous system is currently matter of debate, we 
      report here that once injected into the striatum of 
      1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice, pure 
      populations of either bone marrow neural crest stem cells (NCSC) or mesenchymal 
      stem cells (MSC) survived only transiently into the lesioned brain. Moreover, 
      they do not migrate through the brain tissue, neither modify their initial 
      phenotype, while no recovery of the dopaminergic system integrity was observed. 
      Consequently, we tend to conclude that MSC/NCSC are not able to replace lost 
      neurons in acute MPTP-lesioned dopaminergic system through a suitable integration 
      and/or differentiation process. Altogether with recent data, it appears that 
      neuroprotective, neurotrophic and anti-inflammatory features characterizing BMSC 
      are of greater interest as regards CNS lesions management.
FAU - Neirinckx, Virginie
AU  - Neirinckx V
AD  - Groupe Interdisciplinaire de Genoproteomique Appliquee (GIGA), Unit of 
      Neurosciences, University of Liege, Liege, Belgium.
FAU - Marquet, Alice
AU  - Marquet A
FAU - Coste, Cecile
AU  - Coste C
FAU - Rogister, Bernard
AU  - Rogister B
FAU - Wislet-Gendebien, Sabine
AU  - Wislet-Gendebien S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130531
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 9P21XSP91P (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
SB  - IM
ECI - PLoS One. 2021 Oct 28;16(10):e0256488. doi: 10.1371/journal.pone.0256488. PMID: 
      34710116
MH  - 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
MH  - Animals
MH  - Bone Marrow Cells/*cytology/physiology
MH  - Brain Injuries/chemically induced/pathology/*therapy
MH  - Cell Death
MH  - Dopaminergic Neurons/pathology
MH  - Mesenchymal Stem Cells/*cytology/physiology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Transgenic
MH  - Neural Stem Cells/*cytology/physiology
MH  - *Stem Cell Transplantation
MH  - Treatment Failure
PMC - PMC3669410
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2013/06/07 06:00
MHDA- 2014/02/19 06:00
PMCR- 2013/05/31
CRDT- 2013/06/07 06:00
PHST- 2013/03/20 00:00 [received]
PHST- 2013/04/18 00:00 [accepted]
PHST- 2013/06/07 06:00 [entrez]
PHST- 2013/06/07 06:00 [pubmed]
PHST- 2014/02/19 06:00 [medline]
PHST- 2013/05/31 00:00 [pmc-release]
AID - PONE-D-13-12071 [pii]
AID - 10.1371/journal.pone.0064723 [doi]
PST - epublish
SO  - PLoS One. 2013 May 31;8(5):e64723. doi: 10.1371/journal.pone.0064723. Print 2013.
